Gynecologic Disease Site

Gynecologic Disease Site


ID
Sort
Study Title
 
Status
Sort  
CX6 (GINECO SENTICOL III)

International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer SENTICOL III


NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: Intergroup Led Trial
Status: Planned

Chair: (Canada) Dr. Vanessa Samouelian, CHUM-Centre Hospitalier de l'Universite de Montreal, (514) 890-8444


Planned
I240


NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: CCTG Led Trial
Status: Planned

Chair: (Canada) Dr. Helen J. MacKay, Odette Cancer Centre, (416) 480-5145


Planned
OV26 (CRUK/UCL ICON9)

An International Phase III Randomised Study to Evaluate the Efficacy of Maintenance Therapy with Olaparib and Cediranib or Olaparib Alone in Patients with Relapsed Platinum-sensitive Ovarian Cancer Following a Response to Platinum-Based Chemotherapy


Complexity Level: 2

NCT Registration ID (from clinicaltrials.gov): NCT03278717
NCI US Affiliation: No
Clinical Trials Application (Canada): Yes
Coordination: Intergroup Led Trial
Status: Planned

Chair: (Canada) Dr. Helen J. MacKay, Odette Cancer Centre, (416) 480-5145


Planned
OV27

Immune Therapy in Clear Cell Ovarian Cancer (ITICC)


NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: CCTG Led Trial
Status: Planned

Planned
ENC1 (NRG GY018)

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC#776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin, works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel and carboplatin are chemotherapy drugs used as part of the usual treatment approach for this type of cancer. This study aims to assess if adding immunotherapy to these drugs is better or worse than the usual approach for treatment of this cancer


Complexity Level: 2

Eligibility: women with measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial cancer.

Objectives: Primary Objective: To evaluate the efficacy of pembrolizumab in combination with paclitaxel and carboplatin in patients with advanced stage (measurable stage III or IVA), stage IVB and recurrent endometrial cancer. Efficacy will be determined via investigator assessed progression free survival (PFS) in two distinct populations referred to as proficient and deficient mismatch repair (pMMR and dMMR).

NCT Registration ID (from clinicaltrials.gov): NCT03914612
Participation: Open to member centres
NCI US Affiliation: Yes
Clinical Trials Application (Canada): Yes
Coordination: Intergroup Led Trial
Status: Open to Accrual
Activation Date: October 29, 2019

Chair: (Canada) Dr. Stephen Welch, London Regional Cancer Program, (519) 685-8640


Open to Accrual
OV25

A Randomized Phase II Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer in Women with BRCA 1/2 Mutations (STICs and STONEs)

The purpose of this randomized phase II trial is to find out whether Acetylsalicylic Acid (ASA), commonly known as Asprin, can prevent or reduce the risk of early ovarian cancer in women at high risk for ovarian cancer (with a high-risk gene mutation, BRCA1 or BRCA2). The researchers will test the tissue samples revmoved by surgery to see if taking ASA before the surgery can reduce the risk of ealry or small cancer. This study will also test some biomarkers that might help predict which women are most likely to be affected by the study drug.


Complexity Level: 2

Eligibility: Women with documented germline BRCA 1/2 mutations, scheduled to undergo risk-reducing surgery (bilateral salpingo-oophorectomy or bilateral salpingectomy inclusive of fimbria) within 6 months to 2 years after the date of randomization.

Objectives: PRIMARY OBJECTIVE: To compare the frequency of pre- & early-malignant lesions (serous tubal intraepithelial carcinomas (STICs) or serous tubal occult neoplasias - early (STONEs) in the fallopian tube, at the time of risk reducing surgery. SECONDARY OBJECTIVE: To assess subject acceptance of ASA intervention in a female cohort at high risk for ovarian cancer. TERTIARY OBJECTIVES: (1) To characterize the effect of ASA on high grade serous ovarian cancer (HGSOC) tumourigenesis and to examine the linkage between tumourigenesis and microenvironment. (2) Biobanking for future correlative studies

NCT Registration ID (from clinicaltrials.gov): NCT03480776
Participation: Open to member centres
NCI US Affiliation: No
Clinical Trials Application (Canada): Yes
Coordination: CCTG Led Trial
Status: Open to Accrual
Activation Date: April 06, 2018

Chair: (Canada) Dr. Amit M. Oza, Univ. Health Network-OCI/Princess Margaret Hospital, (416) 946-2818, (Canada) Dr. Stephanie Lheureux, University Health Network, (416) 946-4501 Ext. 2415


Open to Accrual
OVC2 (NRG GY005)

A Randomized Phase II/III study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory). Cediranib maleate and olaparib may stop the growth of tumor cells by blocking enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cediranib maleate and olaparib together may cause more damage to cancer cells when compared to either drug alone or standard chemotherapy.


Complexity Level: 2

Eligibility: women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer

Objectives: Primary Objective: To assess the efficacy and identify (in)active arm(s) of the combination of cediranib and olaparib, cediranib alone, olaparib alone, and physician's choice standard of care chemotherapy, as measured by PFS in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. Secondary Objectives: - To assess the efficacy of the combination of cediranib and olaparib, cediranib alone, olaparib alone, and physician's choice standard of care chemotherapy, as measured by objective response rate (ORR: partial or complete response) by RECIST criteria, in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. - To assess safety endpoints, as measured by frequency and severity of adverse events by Common Terminology Criteria for Adverse Events

NCT Registration ID (from clinicaltrials.gov): NCT02502266
Participation: Open to member centres
NCI US Affiliation: Yes
Clinical Trials Application (Canada): Yes
Coordination: Intergroup Led Trial
Status: Open to Accrual
Activation Date: January 19, 2017

Chair: (Canada) Dr. Diane Provencher, CHUM-Centre Hospitalier de l'Universite de Montreal, (514) 890-8444


Open to Accrual
CX5 (CX5)

A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients with Low-Risk Early Stage Cervical Cancer. (SHAPE)


Complexity Level: 1

Eligibility: Histologically confirmed adenocarcinoma, squamous, or adenosquamous cancer of the cervix. Diagnosis has been made by LEEP, cone or cervical biopsy and has been reviewed and confirmed by the local reference gynecological pathologist.

Objectives: Evaluate whether treatment with radical hysterectomy and pelvic node dissection is non-inferior to treatment with simple hysterectomy and pelvic node dissection in terms of pelvic-relapse free survival. Compare the rates of treatment-related toxicity, extrapelvic relapse-free survival, and overall survival. Compare rates of sentinel node detection, and rates of parametrial, margins and pelvic nodes involvement Compare quality of life (including sexual health)

NCT Registration ID (from clinicaltrials.gov): NCT01658930
Participation: Open to member centres
NCI US Affiliation: No
Clinical Trials Application (Canada): Yes
Coordination: NCIC CTG Led Trial
Status: Closed to Accrual
Activation Date: August 02, 2012 Closing Date: November 29, 2019

Chair: (The Netherlands) Dr. Cor de Kroon, The Dutch Gynecological Oncology Group (DGOG), (61) 540-8037, (Canada) Dr. Marie Plante, CHUQ - Hotel-Dieu de Quebec, (418) 691-5392


Closed to Accrual
EN7 (DCGOG PORTEC-3)

Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma.


Complexity Level: 2

Eligibility: Histologically confirmed endometrial carcinoma, grade of differentiation determined according to the FIGO/AFIP criteria, with one of the following postoperative FIGO 2009 stages; confirmed at pathology review: Stage IA with myometrial invasion, grade 3 with documented lymph-vascular space invasion (LVSI); Stage IB grade 3; Stage II; Stage IIIA or IIIC; or IIIB if parametrial invasion; Stage IA with myometrial invasion, IB, II or IIIA/C with serous or clear cell histology.

Objectives: Overall and failure free survival; toxicity; Quality of Life; Pelvic and distant recurrence; Translational studies on paraffin fixed tissue.

NCT Registration ID (from clinicaltrials.gov): NCT00411138
Participation: Open to member centres
NCI US Affiliation: No
Clinical Trials Application (Canada): Yes
Coordination: Intergroup Led Trial
Status: Closed to Accrual
Activation Date: September 03, 2008 Closing Date: December 20, 2013

Chair: (Canada) Dr. Anthony Fyles, Univ. Health Network-OCI/Princess Margaret Hospital, (416) 946-6522, (The Netherlands) Dr. Carien L. Creutzberg, The Dutch Gynecological Oncology Group (DGOG), (71) 526-3052, (Canada) Dr. Paul Bessette, Centre hospitalier universitaire de Sherbrooke, (819) 346-1110 Ext. 13120


Closed to Accrual
OVC1 (NRG GY004)

A Phase III Study Comparing Single-agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-based Chemotherapy in Women with Recurrent Platinum-sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer


Complexity Level: 2

Eligibility: women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer

Objectives: Primary Objective: Assess the efficacy of either single agent olaparib or the combination of cediranib and olaparib, as measured by PFS, as compared to standard platinum-based chemotherapy in the setting of recurrent platinum-sensitive ovarian, primary peritoneal or fallopian tube cancer. Secondary Objectives:Assess the efficacy of single agent olaparib or the combination of cediranib and olaparib, as measured by response rate, and overall survival as compared to standard platinum-based chemotherapy in the setting of recurrent platinum-sensitive ovarian, primary peritoneal or fallopian tube cancer.

NCT Registration ID (from clinicaltrials.gov): NCT02446600
Participation: Open to member centres
NCI US Affiliation: Yes
Clinical Trials Application (Canada): Yes
Coordination: Intergroup Led Trial
Status: Closed to Accrual
Activation Date: January 04, 2017 Closing Date: November 10, 2017

Chair: (Canada) Dr. Helen J. MacKay, Odette Cancer Centre, (416) 480-5145


Closed to Accrual
CX1

A Phase II Study to Evaluate the Toxicity and Efficacy of Concurrent Cisplatin and Radiation Therapy in the Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Cervix


NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: May 01, 1990 Closing Date: April 12, 1991

Chair: (Canada) Dr. Robert Pearcey, Cross Cancer Institute, (780) 432-8755


Permanently Closed
CX2

A Phase III Study Comparing Concurrent Cisplatin and Radiation Therapy versus Radiation Alone for Locally Advanced Squamous Cell Carcinoma of the Cervix


NCT Registration ID (from clinicaltrials.gov): no NCT
NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: April 12, 1991 Closing Date: September 30, 1996

Chair: (Canada) Dr. Robert Pearcey, Cross Cancer Institute, (780) 432-8755


Permanently Closed
CX3

A Phase III Randomized Study of Cisplatin Alone versus a Combination of Etoposide, Ifosfamide and Cisplatin (VIP) in the Treatment of Persistent, Recurrent or Advanced Squamous or Adenosquamous Cell Carcinoma of the Cervix


NCT Registration ID (from clinicaltrials.gov): no NCT
NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: October 16, 1992 Closing Date: November 19, 1993

Permanently Closed
CX4 (0191)

Phase III trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 g/L with Erythropoietin Versus Above 100 g/L without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer


Complexity Level: 2

Eligibility: Patients with primary, previously untreated, histologically confirmed invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix, Stage II-B, III-B, IV-A.

Objectives: To assess the efficacy of raising and maintaining patient hemoglobin level above 120 g/L using erythropoietin compared to maintenance level above 100 g/L without erythropoietin on progression-free survival, overall survival and local control in anemic patients with carcinoma of the cervix receiving concurrent radiation and cisplatin treatment.

NCT Registration ID (from clinicaltrials.gov): NCT00017004
Participation: Open to member centres
NCI US Affiliation: Yes
Clinical Trials Application (Canada): Yes
Coordination: Intergroup Led Trial
Status: Permanently Closed
Activation Date: October 19, 2001 Closing Date: January 17, 2004

Chair: (Canada) Dr. Peter S. Craighead, Tom Baker Cancer Centre, (403) 521-3701


Permanently Closed
CXC1 (0219)

A Phase III, Randomized Trial of Weekly Cisplatin and Radiation versus Cisplatin and Tirapazamine and Radiation in Stage 1B2, IIA, IIB, IIIB and IVA Cervical Carcinoma Limited to the Pelvis.


Complexity Level: 2

Eligibility: Patients with histologically confirmed invasive squamous cell, adenocarcinoma, or adenosquamous carcinoma of the cervix stages IB2, IIA, IIB, IIIB or IVA.

Objectives: To determine if combining TPZ with cisplatin during radiation therapy increases recurrence-free survival(RFS) when compared with weekly cisplatin and radiation therapy in this patient population.

NCT Registration ID (from clinicaltrials.gov): NCT00262821
Participation: Open to member centres
NCI US Affiliation: Yes
Clinical Trials Application (Canada): Yes
Coordination: Intergroup Led Trial
Status: Permanently Closed
Activation Date: July 20, 2006 Closing Date: September 01, 2009

Chair: (Canada) Dr. Peter S. Craighead, Tom Baker Cancer Centre, (403) 521-3701


Permanently Closed
EN1

Chemotherapy of Stage IV Metastatic and Recurrent Carcinoma of the Uterine Corpus


NCT Registration ID (from clinicaltrials.gov): no NCT
NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: July 06, 1975 Closing Date: November 11, 1980

Permanently Closed
EN4 (55874)

Intergroup (EORTC, NCIC CTG) Phase III Study to Evaluate the Role of Adjuvant Radiotherapy in the Treatment of Uterine Sarcomas Stages I and II


NCT Registration ID (from clinicaltrials.gov): NCT00002459
NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: Intergroup Led Trial
Status: Permanently Closed
Activation Date: June 26, 1995 Closing Date: August 10, 2001

Chair: (Sweden) Dr. N. Einhorn, Radiumhemmet


Permanently Closed
EN5

A Phase III Randomized Trial Comparing TAH BSO versus TAH BSO Plus Adjuvant Pelvic Irradiation in Intermediate Risk, Carcinoma of the Endometrium


Eligibility: Patients with histologically confirmed adenocarcinoma of the endometrium (Stage IA [grade 3] or IB [grade 3] or IC [grade 1 or 2 or 3]) or stage IIA treated by total abdominal hysterectomy with bilateral salpingo-oophorectomy who have not received prior pelvic radiotherapy. Patients may receive first-line brachytherapy (if local standard).

Objectives: In collaboration with the MRC UK ASTEC trial analysis, to compare overall survival; to evaluate the differences in recurrence-free survival, duration of pelvic control and toxicity and tolerability. Canadian components to analyse quality of life and sexual health.

NCT Registration ID (from clinicaltrials.gov): NCT00002807
Participation: Not limited
NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: July 04, 1996 Closing Date: March 31, 2005

Chair: (Canada) Dr. Himu Lukka, Juravinski Cancer Centre at Hamilton Health Sciences, (905) 387-9495 Ext. 64701, (Canada) Dr. Timothy J. Whelan, Juravinski Cancer Centre at Hamilton Health Sciences, (905) 387-9495


Permanently Closed
GT1 (0174)

A Randomized Phase III Trial of Weekly Parenteral Methotrexate Versus "Pulsed" Dactinomycin for Primary Management of Low Risk Gestational Trophoblastic Neoplasia


Eligibility: Patients with untreated, histologically confirmed low risk GTN (persistent hydatidform mole or choriocarcinoma). Patients must have a pretreatment WHO score of 0 - 6 and a GOG performance status of 0 - 2.

Objectives: To determine whether weekly parenteral methotrexate or "pulsed" dactinomycin is the more effective treatment for low risk gestational trophoblastic neoplasia. To prospectively determine and compare the toxicity of each regimen. To prospectively determine whether the definition of persistent GTN is accurate.

NCT Registration ID (from clinicaltrials.gov): NCT00003702
Participation: Open to member centres
NCI US Affiliation: Yes
Clinical Trials Application (Canada): No
Coordination: Intergroup Led Trial
Status: Permanently Closed
Activation Date: October 18, 2000 Closing Date: February 26, 2007

Chair: (Canada) Dr. Diane Provencher, CHUM-Centre Hospitalier de l'Universite de Montreal, (514) 890-8444


Permanently Closed
I102

NCIC CTG Phase II Study of BMS-182751 (JM-216) in Patients With Advanced and/or Recurrent Squamous Cell Carcinoma of the Cervix


NCT Registration ID (from clinicaltrials.gov): no NCT
NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: January 27, 1997 Closing Date: February 16, 1999

Chair: (Canada) Dr. Gavin Stuart, University of British Columbia, (604) 822-5767, (Canada) Dr. Marc G. Trudeau, The Medicine Cancer Centre, (403) 529-8817


Permanently Closed
I106

NCIC CTG Phase II Study of Topotecan/Cisplatin/Paclitaxel as First-Line Chemotherapy for Patients With Advanced Ovarian Cancer


NCT Registration ID (from clinicaltrials.gov): no NCT
NCI US Affiliation: No
Clinical Trials Application (Canada): Yes
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: June 10, 1997 Closing Date: May 07, 1998

Chair: (Canada) Dr. Paul J. Hoskins, BCCA - Vancouver Cancer Centre, (604) 877-6000 Ext. 2365


Permanently Closed
I106B

Phase II Study of Topotecan/Cisplatin Followed by Paclitaxel/Carboplatin as First-Line Chemotherapy for Patients With Advanced Ovarian Cancer


NCT Registration ID (from clinicaltrials.gov): no NCT
NCI US Affiliation: No
Clinical Trials Application (Canada): Yes
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: April 27, 1999 Closing Date: December 16, 1999

Chair: (Canada) Dr. Paul J. Hoskins, BCCA - Vancouver Cancer Centre, (604) 877-6000 Ext. 2365


Permanently Closed
I116

NCIC CTG Phase II Study of CGP 69846A (ISIS 5132) in Recurrent Epithelial Ovarian Cancer


NCT Registration ID (from clinicaltrials.gov): NCT00003892
NCI US Affiliation: No
Clinical Trials Application (Canada): Yes
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: February 01, 1999 Closing Date: May 05, 2000

Chair: (Canada) Dr. Amit M. Oza, Univ. Health Network-OCI/Princess Margaret Hospital, (416) 946-2818


Permanently Closed
I12

NCIC CTG Phase II Study of CBDCA in Ovary


NCT Registration ID (from clinicaltrials.gov): no NCT
NCI US Affiliation: Yes
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: August 01, 1984 Closing Date: February 21, 1985

Permanently Closed
I126

A Phase II Study of Letrozole in Patients With Advanced or Recurrent Endometrial Cancer


NCT Registration ID (from clinicaltrials.gov): NCT00004251
NCI US Affiliation: No
Clinical Trials Application (Canada): Yes
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: January 19, 2000 Closing Date: May 16, 2001

Chair: (Canada) Dr. Amit M. Oza, Univ. Health Network-OCI/Princess Margaret Hospital, (416) 946-2818, (Canada) Dr. Anthony Fyles, Univ. Health Network-OCI/Princess Margaret Hospital, (416) 946-6522


Permanently Closed
I138

NCIC CTG Randomized Phase II Study of NX211 Given by Two Different Intravenous Schedules in Advanced and/or Recurrent Epithelial Ovarian Cancer


Eligibility: Histologically documented advanced and/or recurrent epithelial ovarian cancer (primary fallopian or peritoneal cancer also eligible). One or two prior regimens of chemotherapy required with at least one regimen containing cisplatin or carboplatin. At least one site unidimensional disease.

Objectives: To evaluate, in parallel, the efficacy of two treatment schedules of NX211 as determined by objective response and tumour marker (CA125) in patients with advanced and/or recurrent ovarian cancer. To evaluate the safety, time to progression, and pharmacokinetics of both treatment schedules.

NCT Registration ID (from clinicaltrials.gov): NCT00010179
NCI US Affiliation: No
Clinical Trials Application (Canada): Yes
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: October 31, 2000 Closing Date: September 21, 2001

Chair: (UK) Prof. Hilary Calvert, Newcastle General Hospital, (191) 273-1631


Permanently Closed
I148

A Phase II Study of OSI-774 (NSC 718781) in Patients With Locally Advanced and/or Metastatic Carcinoma of the Endometrium


Eligibility: Patients with histologically documented endometrial cancer. Clinically and/or radiologically documented disease. Unidimensionally measurable disease. Tumour tissue available from primary tumour to assess EGFR status. Patients may have had up to one prior hormonal treatment (adjuvant or metastatic). No prior chemotherapy permitted. No prior EGFR targetting therapy permitted.

Objectives: To assess the efficacy (response rate and duration of stable disease) of OSI-774 given daily to patients with advanced/metastatic carcinoma of the endometrium. To assess toxicity, time to progression and response duration of OSI-774 in this patient population. To correlate objective tumour response with EGFR expression from primary tumour in these patients. To explore patterns of change in markers of EGFR activation in patients that have biopsies (additional investigations).

NCT Registration ID (from clinicaltrials.gov): NCT00030485
NCI US Affiliation: Yes
Clinical Trials Application (Canada): Yes
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: January 10, 2002 Closing Date: March 16, 2004

Chair: (Canada) Dr. Amit M. Oza, Univ. Health Network-OCI/Princess Margaret Hospital, (416) 946-2818, (Canada) Dr. Anthony Fyles, Univ. Health Network-OCI/Princess Margaret Hospital, (416) 946-6522


Permanently Closed
I149

A Phase II Study Of OSI-774 (NSC 718781) Given In Combination With Carboplatin In Patients With Recurrent Epithelial Ovarian Cancer


Eligibility: Patients with histologically documented epithelial ovarian cancer. Clinically and/or radiologically documented disease. Unidimensionally measurable disease. Tumour tissue available from primary tumour to assess EGFR status. Up to 2 prior chemotherapy regimens with the first regimen containing carboplatin or cisplatin. Patients MUST have responded to platinum based first-line chemotherapy. No prior EGFR targeting therapy permitted.

Objectives: To assess the efficacy (response rate and duration of stable disease) of OSI-774 given daily to patients with advanced ovarian carcinoma who are reveiving carboplatin. To assess toxicity, time to progression and response duration of OSI-774 in this patient population. To correlate objective tumour response with EGFR status from primary tumour in these patients. To explore patterns of change in EGFR markers in patients that have biopsies and/or ascitic taps (additional investigations). To assess CA 125 response in patients with elevated CA 125 levels at study entry.

NCT Registration ID (from clinicaltrials.gov): NCT00030446
NCI US Affiliation: Yes
Clinical Trials Application (Canada): Yes
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: January 10, 2002 Closing Date: June 01, 2004

Chair: (Canada) Dr. Hal Hirte, Juravinski Cancer Centre at Hamilton Health Sciences, (905) 387-9495


Permanently Closed
I160

A Phase II Study Of CCI-779 In Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer


Complexity Level: 2

Eligibility: Patients with histologically documented endometrial cancer. Clinically and/or radiologically documented disease. Unidimensionally measurable disease. Tumour tissue available from primary tumour to assess molecular markers of CCI-779 activation. Group A patients may have had up to one prior hormonal treatment (adjuvant or metastatic) with no prior chemotherapy permitted. Group B patients may have had an unlimited number of prior hormonal treatments (adjuvant or metastatic) and must have had one cycle of cytotoxic chemotherapy.

Objectives: To assess the efficacy (response rate and duration of stable disease) of CCI-779 given IV weekly in patients with metastatic and/or locally advanced recurrent carcinoma of the endometrium. To assess the adverse events, time to progression and response duration of CCI-779 given IV weekly in patients with metastatic and/or locally advanced recurrent carcinoma of the endometrium. To correlate objective tumour response with PTEN expression in the tumour tissue obtained at diagnosis (primary tumour). To explore the relatinoship between objective tumour response with other molecular measures in diagnostic tumour tissue.

NCT Registration ID (from clinicaltrials.gov): NCT00072176
Participation: Limited to invited centres only.
NCI US Affiliation: Yes
Clinical Trials Application (Canada): Yes
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: January 14, 2004 Closing Date: June 15, 2007

Chair: (Canada) Dr. Amit M. Oza, Univ. Health Network-OCI/Princess Margaret Hospital, (416) 946-2818, (Canada) Dr. Laurie Elit, Juravinski Cancer Centre at Hamilton Health Sciences, (905) 389-5688


Permanently Closed
I184

A Phase II Study of Sunitinib, an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients with Unresectable, Locally Advanced or Metastatic Cervical Carcinoma


Eligibility: Patients with histological/cytological documented squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma of the cervix (advanced, recurrent or persistent disease). Maximum of 1 prior chemotherapy regimen for metastatic disease. Prior neoadjuvant, adjuvant or concurrent chemoradiartion is permitted.

Objectives: To assess the efficacy (objective response rate) of sunitinib given orally daily for 4 out of every 6 weeks in patients with unresectable, locally advanced or metastatic carcinoma of the cervix. To assess the toxicity of sunitinib in patients with unresectable, locally advanced or metastatic carcinoma of the cervix. To document time to progression, early objective progression rate, and, if objective responses are observed, response duration.

NCT Registration ID (from clinicaltrials.gov): NCT00389974
Participation: Limited to invited centres
NCI US Affiliation: Yes
Clinical Trials Application (Canada): Yes
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: November 09, 2006 Closing Date: May 12, 2008

Chair: (Canada) Dr. Helen J. MacKay, Odette Cancer Centre, (416) 480-5145


Permanently Closed
I185

A Phase II Study Of Sunitinib (SU11248; NSC 736511) In Patients With Recurrent Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma


Eligibility: Patients with histological documented epithelial ovarian, fallopian tube carcinoma or primary peritoneal cancer (advanced or metastatic disease). Minimum of 1 and maximum of 2 prior chemotherapy regimens, one of which must be platinum containing.

Objectives: To assess the efficacy (response rate) of sunitinib given orally daily for 4 out of every 6 weeks in patients with advanced or metastatic previously treated epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. To assess the toxicity of sunitinib in patients with advanced or metastatic previously treated epithelial ovarian, fallopian tube or primary peritoneal carcinoma. To document CA125 response rate, early objective progression rate, and, if objective responses are observed, response duration.

NCT Registration ID (from clinicaltrials.gov): NCT00388037
Participation: Limited to invited centres
NCI US Affiliation: Yes
Clinical Trials Application (Canada): Yes
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: November 10, 2006 Closing Date: April 17, 2008

Chair: (Canada) Dr. James Biagi, Cancer Centre of Southeastern Ontario at Kingston, (613) 549-6666 Ext. 4503


Permanently Closed
I192

A Phase II Study of Ridaforolimus in Patients with Metastatic and/or Locally Advanced Recurrent Endometrial Cancer


Complexity Level: 2

Eligibility: Patients with histologically documented endometrial cancer. Clinically and/or radiologically documented disease. Unidimensionally measurable disease. Tumour tissue available from primary tumour to assess molecular markers of deforolimus activation. Prior hormonal treatment (adjuvant or metastatic), but no prior chemotherapy permitted.

Objectives: To assess the efficacy (response rate and duration of stable disease) of ridaforolimus given orally, once daily, 5 days/week continuously in patients with metastatic and/or locally advanced recurrent carcinoma of the endometrium. To assess the adverse events, time to progression and response duration of ridaforolimus in patients with metastatic and/or locally advanced recurrent carcinoma of the endometrium. To correlate objective tumour response with PTEN expression in the tumour tissue obtained at diagnosis (primary tumour).

NCT Registration ID (from clinicaltrials.gov): NCT00770185
Participation: Limited to invited centres
NCI US Affiliation: No
Clinical Trials Application (Canada): Yes
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: August 26, 2008 Closing Date: August 11, 2010

Chair: (Canada) Dr. Amit M. Oza, Univ. Health Network-OCI/Princess Margaret Hospital, (416) 946-2818


Permanently Closed
I199

A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients with Recurrent, Unresectable, Locally Advanced or Metastatic Carcinoma of the Cervix.


Complexity Level: 2

Eligibility: Patients with histologically or cytologically confirmed squamous cell carcinoma or adenosquamous carcinoma of the cervix, or adenocarcinoma of the cervix. Clinically and/or radiologically documented disease. Only one prior chemotherapy regimen allowed. Patient must be > 4 weeks since chemotherapy, radiation therapy and surgery. No prior treatment with an mTOR inhibitor. Patient must have tumour tissue from their primary tumour available.

Objectives: 1.1 To assess the efficacy (objective response rate) of temsirolimus given IV weekly in patients with metastatic and/or locally advanced recurrent carcinoma of the cervix. 1.2 To assess the adverse events, time to progression and response duration of temsirolimus given IV weekly in patients with metastatic and/or locally advanced recurrent carcinoma of the cervix. 1.3 To explore the relationship between expression of proteins in the mTOR pathway in archival tissue samples from patients on this trial and their objective response to therapy.

NCT Registration ID (from clinicaltrials.gov): NCT01026792
Participation: Limited to invited centres
NCI US Affiliation: Yes
Clinical Trials Application (Canada): Yes
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: December 17, 2009 Closing Date: October 27, 2011

Chair: (Canada) Dr. Anna Tinker, BCCA - Vancouver Cancer Centre, (604) 877-6000 Ext. 2707, (Canada) Dr. Helen J. MacKay, Odette Cancer Centre, (416) 480-5145


Permanently Closed
I25

NCIC CTG Phase II Study of Trimetrexate in Ovary


NCT Registration ID (from clinicaltrials.gov): no NCT
NCI US Affiliation: Yes
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: July 28, 1986 Closing Date: May 02, 1988

Permanently Closed
I51

NCIC CTG Phase I Study of GM-CSF + Carboplatin/Cyclophosphamide in Ovary


NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: May 29, 1989 Closing Date: February 10, 1990

Permanently Closed
I51A

NCIC CTG Phase I Study of GM-CSF Plus Carboplatin in Ovary


NCT Registration ID (from clinicaltrials.gov): no NCT
NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: February 10, 1990 Closing Date: September 28, 1990

Permanently Closed
I59

NCIC CTG Phase I Study of IL-3 in Patients With Relapsed Ovarian Cancer Receiving Carboplatin


NCT Registration ID (from clinicaltrials.gov): no NCT
NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: December 10, 1990 Closing Date: March 27, 1992

Permanently Closed
I74

NCIC CTG Phase I Study of Biweekly Taxol/Cisplatin as Initial Chemotherapy for Ovarian Cancer


NCT Registration ID (from clinicaltrials.gov): no NCT
NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: November 02, 1992 Closing Date: October 07, 1994

Chair: (Canada) Dr. Paul J. Hoskins, BCCA - Vancouver Cancer Centre, (604) 877-6000 Ext. 2365


Permanently Closed
I82

NCIC CTG Randomized Phase II Study of Topotecan in Previously Treated Patients With Ovarian Cancer


NCT Registration ID (from clinicaltrials.gov): no NCT
NCI US Affiliation: Yes
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: July 08, 1994 Closing Date: April 22, 1997

Chair: (Canada) Dr. Paul J. Hoskins, BCCA - Vancouver Cancer Centre, (604) 877-6000 Ext. 2365


Permanently Closed
OV1

Treatment of Patients With Advanced Ovarian Carcinoma (Stages III and IV) With Melphalan, 5 Fluorouracil and Methotrexate in Combination and Sequentially


NCT Registration ID (from clinicaltrials.gov): no NCT
NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: April 04, 1974 Closing Date: March 07, 1977

Permanently Closed
OV10 (55931)

Intergroup Phase III Comparison of a Combination of TAXOL-Platinum and a Combination of Cyclophosphamide-Platinum Chemotherapy in the Treatment of Advanced Epithelial Ovarian Cancer.


NCT Registration ID (from clinicaltrials.gov): no NCT
NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: Intergroup Led Trial
Status: Permanently Closed
Activation Date: June 03, 1994 Closing Date: July 31, 1995

Chair: (Canada) Dr. Gavin Stuart, University of British Columbia, (604) 822-5767, (Belgium) Dr. Martine Piccart, Institut Jules Bordet, (2) 541-3111


Permanently Closed
OV11 (9619)

A Phase II Trial of Intraperitoneal Cisplatin and Intravenous and Intraperitoneal Paclitaxel in Women with Optimally-Debulked Stage III Epithelial Ovarian Cancer


NCT Registration ID (from clinicaltrials.gov): no NCT
NCI US Affiliation: Yes
Clinical Trials Application (Canada): No
Coordination: Intergroup Led Trial
Status: Permanently Closed
Activation Date: June 21, 1996 Closing Date: May 15, 1998

Permanently Closed
OV12

A Phase III Comparison of BAY 12-9566 versus Placebo as Consolidation After Standard Chemotherapy in Patients with Epithelial Ovarian Cancer


NCT Registration ID (from clinicaltrials.gov): no NCT
NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: May 06, 1998 Closing Date: September 20, 1999

Chair: (Canada) Dr. Hal Hirte, Juravinski Cancer Centre at Hamilton Health Sciences, (905) 387-9495


Permanently Closed
OV13 (EORTC 55971)

An International Multi-Centre Randomized Phase III Study Comparing Upfront Debulking Surgery Versus Neo-Adjuvant Chemotherapy in Patients With Stage IIIC or IV Epithelial Ovarian Carcinoma


Complexity Level: 2

Eligibility: Patients with histologically confirmed stage IIIc or IV epithelial ovarian, peritoneal or fallopian tube carcinoma with a performance status of < 2 (WHO), adequate blood counts and liver and renal function.

Objectives: To compare overall survival; to evaluate the differences in progression free survival, toxicity and tolerability and quality of life.

NCT Registration ID (from clinicaltrials.gov): NCT00003636
Participation: Open to member centres
NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: Intergroup Led Trial
Status: Permanently Closed
Activation Date: May 13, 1999 Closing Date: November 30, 2006

Chair: (Canada) Dr. Gavin Stuart, University of British Columbia, (604) 822-5767


Permanently Closed
OV15 (OVAR 2.5)

International Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients with Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy


Eligibility: Patients with histologically proven ovarian carcinoma with evidence of recurrence or progression, which is not amenable to curative surgery or radiotherapy. Patients must have failed first-line platinum-containing therapy more than 6 months after treatment discontinuation.

Objectives: To compare the time to progressive disease (TTPD) in patients treated with gemcitabine plus carboplatin versus carboplatin monotherapy. The secondary objectives of this study are to compare the following in the two arms: response rate, duration of response, survival time, toxicity, and changes in quality of life over time.

NCT Registration ID (from clinicaltrials.gov): NCT00006453
Participation: Open to member centres
NCI US Affiliation: No
Clinical Trials Application (Canada): Yes
Coordination: Intergroup Led Trial
Status: Permanently Closed
Activation Date: October 17, 2000 Closing Date: April 15, 2002

Chair: (Germany) Dr. Jacobus Pfisterer, Staedtisches Klinikum Solingen, (212) 547-2371, (Canada) Dr. Marie Plante, CHUQ - Hotel-Dieu de Quebec, (418) 691-5392


Permanently Closed
OV16 (OV16)

A Phase III Study of Cisplatin Plus Topotecan Followed by Paciltaxel plus Carboplatin versus Paclitaxel plus Carboplatin as First Line Chemotherapy in Women with Newly Diagnosed Advanced Epithelial Ovarian Cancer


Complexity Level: 2

Eligibility: Patients with confirmed epithelial ovarian (or primary fallopian or peritoneal) cancer, Stage IIB to IV, with microscopic or macroscopic residual disease who have not received prior chemotherapy and have evidence of adequate organ function.

Objectives: Primary: to compare progression free survival. Secondary: to compare overall survival, response rates, toxic effects, quality of life, and CA 125 normalization rates.

NCT Registration ID (from clinicaltrials.gov): NCT00028743
Participation: Not limited
NCI US Affiliation: No
Clinical Trials Application (Canada): Yes
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: August 31, 2001 Closing Date: June 29, 2005

Chair: (Canada) Dr. Paul J. Hoskins, BCCA - Vancouver Cancer Centre, (604) 877-6000 Ext. 2365


Permanently Closed
OV17 (CALYPSO)

A Multi-National, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (Caelyx) and Carboplatin vs. Paclitaxel and Carboplatin in Patients with Epithelial Ovarian Cancer in Late Relapse (>6 months): GCIG Calypso Study


Complexity Level: 2

Eligibility: Epithelial cancer of the ovary in progression > 6 months (late relapse) after a first or a second line including a platinum-derivative. Patients should have received previously a taxane.

Objectives: Primary objective: Progression-free survival (PFS) between both treatment groups Secondary objectives Overall survival (OS) Toxicities Quality of life (QOL)

NCT Registration ID (from clinicaltrials.gov): NCT00189553
Participation: Open to member centres
NCI US Affiliation: No
Clinical Trials Application (Canada): Yes
Coordination: Intergroup Led Trial
Status: Permanently Closed
Activation Date: October 17, 2005 Closing Date: September 25, 2007

Chair: (France) Dr. Eric Pujade-Lauraine, Hopital Hotel Dieu, (1) 4234-8325


Permanently Closed
OV19 (MRC ICON7)

A Randomized, Two-Arm, Multi-Center Gynecologic Cancer Intergroup Trial of Adding Bevacizumab To Standard Chemotherapy (Carboplatin And Paclitaxel) In Patients With Epithelial Ovarian Cancer.


Complexity Level: 2

Eligibility: ICON7 will include patients with newly diagnosed, histologically confirmed, high risk FIGO stage I and IIa (Grade 3 or clear cell carcinoma only) and FIGO stage IIb - IV (all grades and all histological types) epithelial ovarian, fallopian tube or primary peritoneal cancer, who have undergone initial surgery (either debulking cytoreductive surgery or a biopsy if the patient has FIGO stage IV disease) and who will not be considered for cytoreductive surgery prior to disease progression. Patients with measurable and non-measurable disease (see Appendix 10) are eligible.

Objectives: Primary: Progression-free survival. Secondary: Overall survival, Response rate (rate and duration), Adverse events, Quality of Life, Health Economics and Translational Research.

NCT Registration ID (from clinicaltrials.gov): NCT00483782
Participation: Open to member centres
NCI US Affiliation: No
Clinical Trials Application (Canada): Yes
Coordination: Intergroup Led Trial
Status: Permanently Closed
Activation Date: March 19, 2007 Closing Date: February 13, 2009

Chair: (Canada) Dr. Amit M. Oza, Univ. Health Network-OCI/Princess Margaret Hospital, (416) 946-2818, (UK) Dr. Timothy Perren, St. James University Hospital, (113) 206-6927, (Canada) Dr. Mark S. Carey, Clinical Research Unit at Vancouver Coastal, (604) 877-6000


Permanently Closed
OV2

A Clinical Trial of Radiotherapy and Chemotherapy With Melphalan Following Surgery for Patients With Limited (Stage I, II & IIIo) Carcinoma of the Ovary


NCT Registration ID (from clinicaltrials.gov): no NCT
NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: May 20, 1975 Closing Date: March 31, 1984

Permanently Closed
OV21 (OV21)

A Phase II Study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy.


Complexity Level: 1

Eligibility: Epithelial Ovarian Cancer Primary Peritoneal Carcinoma Fallopian Tube Carcinoma

Objectives: 9 month progression rate following randomization Progression-Free Survival, Overall Survival, Toxic Effects, Quality of Life

NCT Registration ID (from clinicaltrials.gov): NCT00993655
Participation: Open to member centres
NCI US Affiliation: No
Clinical Trials Application (Canada): Yes
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: September 11, 2009 Closing Date: May 27, 2015

Chair: (Spain) Ms. Ana Oaknin-Benzaquen, GEICO-Sociedad Espanola de Oncologia Medica (SEOM), (Canada) Dr. Helen J. MacKay, Odette Cancer Centre, (416) 480-5145, (Canada) Dr. Diane Provencher, CHUM-Centre Hospitalier de l'Universite de Montreal, (514) 890-8444, (USA) Dr. Deb Armstrong, Southwest Oncology Group, Operations Office, (410) 614-2743, (UK) Dr. Chris Gallagher, UCL Cancer Trials Centre


Permanently Closed
OV3

Second Co-operative Clinical Trial on Treatment of Ovarian Carcinoma


NCT Registration ID (from clinicaltrials.gov): no NCT
NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: March 16, 1978 Closing Date: May 14, 1979

Permanently Closed
OV4

Third Cooperative Clinical Trial on Treatment of Advanced Ovarian Carcinoma


NCT Registration ID (from clinicaltrials.gov): no NCT
NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: December 08, 1980 Closing Date: March 31, 1984

Permanently Closed
OV5A

Pilot Study of Weekly Adriamycin and Cisplatinum With Co-Trimoxazole Coverage in Patients With Stage III And IV Ovarian Cancer


NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: August 22, 1983 Closing Date: May 01, 1984

Permanently Closed
OV6

Non-Randomized Study to Determine the Efficacy of Surgery Alone in Patients With Stage IA Or IB Epithelial Ovarian Carcinoma When Extensive Surgical Staging Has Been Done to Confirm Limited Disease


NCT Registration ID (from clinicaltrials.gov): no NCT
NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: September 10, 1984 Closing Date: March 18, 1988

Permanently Closed
OV7

Clinical Trial Comparing Abdominal-Pelvic Radiation versus Cyclophosphamide and Cisplatin Chemotherapy in Patients With Epithelial Ovarian Carcinoma Having Only Microscopic Residual Disease Following Surgery


NCT Registration ID (from clinicaltrials.gov): no NCT
NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: January 29, 1985 Closing Date: March 16, 1988

Permanently Closed
OV8

Clinical Trial Examining the Treatment of Patients With Macroscopic Residual Epithelial Ovarian Carcinoma. Part I - The Comparison of Cyclophosphamide and Cisplatin Versus Cyclophosphamide and Carboplatin as Initial Treatment Part II - The Comparison of Whole Abdominal Radiation versus Continuing Chemotherapy in Patients on Part I of the Study


NCT Registration ID (from clinicaltrials.gov): no NCT
NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: June 07, 1985 Closing Date: March 17, 1989

Permanently Closed
OV8A

Pilot Study of Cyclophosphamide and Cisplatin in Patients With Ovarian Cancer


NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: December 03, 1984 Closing Date: May 06, 1985

Permanently Closed
OV9

A Multicentre, Randomized Comparative Study of Taxol in Platinum Treated Ovarian Cancer (High vs. Low Dose; Long vs. Short Infusion)


NCT Registration ID (from clinicaltrials.gov): no NCT
NCI US Affiliation: No
Clinical Trials Application (Canada): No
Coordination: NCIC CTG Led Trial
Status: Permanently Closed
Activation Date: August 06, 1991 Closing Date: March 06, 1992

Permanently Closed